Overview
Integrated Drug Creation platform combining generative AI, wet-lab validation, and proprietary pipeline programs including ABS-101 (anti-TL1A), ABS-201 (anti-PRLR), and partner collaborations in dermatology and immunology.
Product and company
Absci — Biotechnology is a verified product offering linked to the Brel Digital company profile for Absci.
Use cases
Integrated Drug Creation platform combining generative AI, wet-lab validation, and proprietary pipeline programs including ABS-101 (anti-TL1A), ABS-201 (anti-PRLR), and partner collaborations in dermatology and immunology.
Target customer
Internal drug development teams, pharmaceutical partners, and investors seeking AI-native antibody design from de novo generation through clinical proof-of-concept.
Technologies
Primary technologies assigned from the linked company profile: Deep Learning, Generative AI, Healthcare Analytics, Machine Learning, Predictive Analytics.
Sources and references
- Official product / company source: https://investors.absci.com/news-releases/news-release-details/absci-announces-first-participants-dosed-phase-1-clinical-trial/
- Supporting source: https://www.absci.com/about/board-of-directors/
Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.
Last reviewed
This product profile was last reviewed on 2026-07-14.
Correction request
If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.
Features and capabilities
- Integrated Drug Creation platform combining generative AI, wet-lab validation, and proprietary pipeline programs includin
- generative AI
- wet-lab validation
- and proprietary pipeline programs including ABS-101 (anti-TL1A)
- ABS-201 (anti-PRLR)
- and partner collaborations in dermatology
- immunology
Extracted from the linked company product description already verified on Brel. No capabilities were invented.